Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/21/2026

1. WMT
2. ROST
3. AAP
4. NVDA
5. SPY

6. SPCX
7. AVGO
8. RMAX
9. HD
10. BJ

Get Alerts CMPX Hot Sheet

Price: $2.40 +1.69%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Stifel Targeted Oncology Days taking place virtually April 16 – 17, 2024.

Presentation detailsDate: Tuesday, April 16Time: 11 – 11:25 AM ET Webcast Link: https://wsw.com/webcast/stifel

Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page.

About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass’s pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. Compass was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics, Inc. website at www.compasstherapeutics.com.

Investor Contact[email protected]

Media ContactAnna Gifford, Communications Manager[email protected] 617-500-8099